BeOne Medicines マネジメント
マネジメント 基準チェック /34
BeOne Medicinesの CEO はJohn Oylerで、 Jan2010年に任命され、 の在任期間は 16.33年です。 の年間総報酬は$ 20.84Mで、 5.3%給与と94.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の3.47%を直接所有しており、その価値は$ 1.14B 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と5年です。
主要情報
John Oyler
最高経営責任者
US$20.8m
報酬総額
| CEO給与比率 | 5.28% |
| CEO在任期間 | 16.3yrs |
| CEOの所有権 | 3.5% |
| 経営陣の平均在職期間 | 3.8yrs |
| 取締役会の平均在任期間 | 5yrs |
経営陣の近況
Recent updates
ONC: Hematology Leadership And 2026 Pipeline Readouts Will Re Rate Shares
BeOne Medicines' updated analyst price target reflects a modest adjustment, with fair value moving by about $1 per share as analysts balance slightly higher revenue and profit margin assumptions with a lower future P/E multiple following recent target changes and mixed rating updates across the Street. Analyst Commentary Recent research updates on BeOne Medicines show a mix of views, but there is a clear cluster of bullish analysts who see support for the current valuation and room for further upside based on execution around core products and the pipeline.
ONC: Hematology Strength And Slower Pipeline Progress Will Shape Fairly Valued Shares
The updated analyst price target for BeOne Medicines shifts to $336 from $321, as analysts factor in slightly higher modeled revenue growth, profit margins, and future P/E assumptions, alongside mixed recent research that includes both trims and increases in published targets. Analyst Commentary Recent research around BeOne Medicines reflects a mix of enthusiasm for its core hematology asset and a more cautious reset on what investors should pay for that story.
ONC: Hematology Pipeline Strength And Upcoming Data Readouts Will Drive Future Upside
BeOne Medicines' analyst price target has been nudged higher to reflect a fair value estimate of about $408, as analysts balance slightly softer long term growth and margin assumptions with ongoing confidence in Brukinsa and the broader hematology pipeline, including support from several recent target hikes and one downgrade to Hold. Analyst Commentary Bullish Takeaways Bullish analysts highlight Brukinsa as a core value driver, treating it as one of the stronger hematology assets and a key pillar supporting current fair value estimates in the low $400s.ONC: Hematology Franchise Strength And Pipeline Readouts Will Re Rate Shares
BeOne Medicines' updated analyst price target has moved lower, reflecting a reduced fair value estimate to $478.80 as analysts factor in more moderate revenue growth, slimmer profit margins, a slightly higher discount rate, and a higher future P/E multiple. This multiple is anchored by strong Brukinsa performance but a slower build for the next wave of assets.ONC: Brukinsa Reliance And Hematology Pipeline Will Shape Fairly Valued Shares
The analyst price target for BeOne Medicines has been nudged higher by about $13 to align with a fair value update to roughly $321. Analysts are factoring in Q4 results, ongoing Brukinsa performance, and a higher future P/E assumption, alongside slightly more conservative revenue growth and profit margin inputs.ONC: Hematology Pipeline Hype Will Pressure Shares If Execution Slips
Analysts have raised their price targets on BeOne Medicines by $9, citing a pipeline they view as underappreciated by the market and supporting that view with updated assumptions regarding growth, profitability, and valuation multiples. Analyst Commentary Recent research has centered on how fully the market is pricing BeOne Medicines' drug pipeline and long term earnings power into the current share price.ONC: Hematology And Solid Tumor Pipeline Progress Will Drive Future Upside
Analysts lifted their price target for BeOne Medicines to about $404, up roughly $3, citing increased conviction in the value of its hematology and solid tumor pipeline, which is reflected in a slightly higher assumed future P/E multiple. Analyst Commentary Recent research updates on BeOne Medicines cluster around a similar theme: bullish analysts are raising price targets and citing comfort with both the hematology and solid tumor franchises, while also highlighting execution risks that investors should keep in mind.ONC: Hematology Franchise And Oncology Pipeline Are Expected To Re Rate Shares
Analysts have lifted their price targets on BeOne Medicines into the low US$400s, and our fair value estimate has edged up to about US$508 as they highlight what they see as underappreciation of the pipeline, the potential for best in class hematology assets, and additional upside from oncology trial updates. Analyst Commentary Recent Street research on BeOne Medicines has tilted clearly positive, with a series of price target increases into the low US$400s range and at least one rating upgrade.ONC: Fair View Balances Blood Cancer Progress With Gastroesophageal Cancer Opportunity
The analyst price target for BeOne Medicines has moved higher to reflect a fair value estimate of $292.03, with analysts pointing to stronger modeled revenue growth and profit margins, supported by recent Street research around Brukinsa performance, Ziihera phase III progress in HER2-positive GEA with Tevimbra, and continued confidence in the CLL and solid tumor pipeline. Analyst Commentary Recent Street research on BeOne Medicines has generally pointed to constructive views on the company’s core franchises, with several price targets adjusted higher alongside updates on Brukinsa, sonrotoclax, and the broader CLL and solid tumor pipeline.ONC: Priority Review And Trial Progress Will Drive Future Upside Momentum
Analysts have nudged their blended price target for BeOne Medicines up by about $3 to roughly $402, citing stronger confidence in the chronic lymphocytic leukemia and solid tumor pipelines, recent Ziihera and Tevimbra data, and repeated quarterly beats that support steadily improving margins despite a slightly higher discount rate. Analyst Commentary Bullish analysts point to a broad set of recent price target hikes in the high $380s to low $420s range as evidence that the market is re-rating BeOne Medicines higher on both execution and pipeline visibility.ONC: Priority Review And Trial Updates Will Drive Momentum Amid Sector Risks
BeOne Medicines’ analyst price target has edged up from $395 to $399, as analysts point to key clinical updates and solid quarterly performance as catalysts for incremental upside. Analyst Commentary Recent research notes from Street analysts highlight both strengths and risks for BeOne Medicines as the company navigates pivotal clinical developments and posts strong financial results.ONC: Pipeline Data And Conference Updates Will Shape Outlook Amid Sector Risks
Analysts have increased their fair value estimate for BeOne Medicines to $395.37 from $382.29, citing strong quarterly results as well as an improved outlook for key therapies and pipeline advancements. Analyst Commentary Bullish analysts emphasized several positive trends in BeOne Medicines' recent performance and outlook, resulting in a series of raised price targets and continued positive ratings.We Think BeOne Medicines' (NASDAQ:ONC) Profit Is Only A Baseline For What They Can Achieve
Nov 14
ONC: Pivotal Oncology Trial Data Will Drive Future Upside Momentum
BeOne Medicines' fair value price target has risen modestly by $1.20 to $382.29. Analysts cite increased confidence in peak sales for sonrotoclax and the company's broadly advancing oncology pipeline as key drivers for the upward adjustment.Oncology Trials And Global Expansion Will Unlock Future Markets
Analysts have raised their fair value price target for BeOne Medicines from $372.97 to $381.09. They cite accelerating revenue growth, an improved profit margin outlook, and positive pivotal trial catalysts as reasons for their more optimistic projections.BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline
Oct 14Oncology Trials And Global Expansion Will Unlock Future Markets
Analysts have increased their fair value price target for BeOne Medicines by approximately $5 to $372.97. They cite robust Q2 sales growth, encouraging pipeline developments, and upward revisions to revenue forecasts as reasons for the adjustment.Oncology Trials And Global Expansion Will Unlock Future Markets
BeOne Medicines’ consensus price target was raised to $367.68, reflecting analyst optimism driven by robust sales growth, positive pipeline updates, profitability, and increased revenue guidance. Analyst Commentary Bullish analysts highlight BeOne Medicines’ broad oncology pipeline and upcoming pivotal data readouts—specifically BTK inhibitor data in mantle cell lymphoma and PD1 inhibitor/anti-HER2 combination results in gastroesophageal cancer—as key drivers for durable growth.Oncology Trials And Global Expansion Will Unlock Future Markets
The consensus analyst price target for BeOne Medicines was raised to $363.30, primarily driven by strong Brukinsa Q2 sales, improved forward revenue guidance, and ongoing pipeline progress. Analyst Commentary Bullish analysts cite robust Q2 sales growth, particularly from Brukinsa in the US and EU, as the main driver for upward price target revisions.Oncology Trials And Global Expansion Will Unlock Future Markets
With both revenue growth and net profit margin expectations remaining essentially unchanged, analysts have maintained BeOne Medicines’ fair value at a consensus price target of $357.18. What's in the News BeOne Medicines raised 2025 revenue guidance to $5.0–$5.3 billion, now expecting positive GAAP operating income.Shareholders Would Not Be Objecting To BeiGene, Ltd.'s (NASDAQ:ONC) CEO Compensation And Here's Why
May 15
US Facility And Phase III Trials Will Expand Markets
Expansion of manufacturing capabilities and global market presence aims to boost revenue and market share, particularly in B-cell malignancies.BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025
Feb 28BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US
Dec 01CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | US$287m |
| Sep 30 2025 | n/a | n/a | US$69m |
| Jun 30 2025 | n/a | n/a | -US$178m |
| Mar 31 2025 | n/a | n/a | -US$392m |
| Dec 31 2024 | US$21m | US$1m | -US$645m |
| Sep 30 2024 | n/a | n/a | -US$822m |
| Jun 30 2024 | n/a | n/a | -US$524m |
| Mar 31 2024 | n/a | n/a | -US$784m |
| Dec 31 2023 | US$19m | US$871k | -US$882m |
| Sep 30 2023 | n/a | n/a | -US$976m |
| Jun 30 2023 | n/a | n/a | -US$2b |
| Mar 31 2023 | n/a | n/a | -US$2b |
| Dec 31 2022 | US$18m | US$800k | -US$2b |
| Sep 30 2022 | n/a | n/a | -US$2b |
| Jun 30 2022 | n/a | n/a | -US$2b |
| Mar 31 2022 | n/a | n/a | -US$2b |
| Dec 31 2021 | US$17m | US$740k | -US$1b |
| Sep 30 2021 | n/a | n/a | -US$1b |
| Jun 30 2021 | n/a | n/a | -US$1b |
| Mar 31 2021 | n/a | n/a | -US$1b |
| Dec 31 2020 | US$14m | US$696k | -US$2b |
| Sep 30 2020 | n/a | n/a | -US$2b |
| Jun 30 2020 | n/a | n/a | -US$1b |
| Mar 31 2020 | n/a | n/a | -US$1b |
| Dec 31 2019 | US$13m | US$675k | -US$949m |
報酬と市場: Johnの 総報酬 ($USD 20.84M ) は、 US市場 ($USD 14.54M ) の同規模の企業の平均を上回っています。
報酬と収益: Johnの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
John Oyler (57 yo)
16.3yrs
在職期間
US$20,836,439
報酬
Mr. John V. Oyler Co-Founded BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 16.3yrs | US$20.84m | 3.47% $ 1.1b | |
| President and Global Head of Research & Development | less than a year | US$7.40m | 0.15% $ 50.4m | |
| Co-Chairman of Scientific Advisory Board | 16.3yrs | US$4.25m | 0.64% $ 211.6m | |
| Chief Financial Officer | 1.8yrs | US$6.93m | 0.022% $ 7.3m | |
| General Counsel | 3.8yrs | US$4.68m | 0.022% $ 7.2m | |
| VP & Chief Accounting Officer | 2.2yrs | データなし | 0.0050% $ 1.6m | |
| Chief Technology Officer | 1yr | データなし | データなし | |
| Head of Investor Relations | no data | データなし | データなし | |
| Senior VP & Head of Corporate Communications | 1.3yrs | データなし | データなし | |
| Senior VP & Chief Medical Officer for Solid Tumors | 4.3yrs | データなし | データなし | |
| Global Head of Human Resources | 5.2yrs | データなし | データなし | |
| Head of External Innovation & Senior VP | 15.6yrs | データなし | データなし |
3.8yrs
平均在職期間
55yo
平均年齢
経験豊富な経営陣: ONCの経営陣は 経験豊富 であると考えられます ( 3.8年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 15.6yrs | US$20.84m | 3.47% $ 1.1b | |
| Co-Chairman of Scientific Advisory Board | 10.3yrs | US$4.25m | 0.64% $ 211.6m | |
| Independent Non-Executive Director & Member of the Scientific Advisory Committee | 11.1yrs | US$484.65k | 0.0044% $ 1.4m | |
| Independent Non-Executive Director and Member of Commercial & Medical Affairs Advis. & SA Committee | 5.8yrs | US$502.40k | 0.0032% $ 1.1m | |
| Chairman of Commercial & Medical Affairs Advisory Committee and Ind. Non Executive Director | 6.3yrs | US$529.65k | 0.0026% $ 849.9k | |
| Member of Scientific Advisory Board | 1.3yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 1.3yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 1.3yrs | データなし | データなし | |
| Independent Non-Executive Director | 1.7yrs | US$303.07k | データなし | |
| Co-Chairman of Scientific Advisory Committee & Director | 4.3yrs | US$494.65k | 0.0032% $ 1.0m | |
| Member of Commercial & Medical Affairs Advisory Committee and Independent Lead Director | 11.6yrs | US$489.90k | 0.0044% $ 1.4m | |
| Member of SA | 4.3yrs | US$514.90k | 0.0032% $ 1.0m |
5.0yrs
平均在職期間
65.5yo
平均年齢
経験豊富なボード: ONCの 取締役会 は 経験豊富 であると考えられます ( 5年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/01 14:15 |
| 終値 | 2026/05/01 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
BeOne Medicines AG 33 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。66
| アナリスト | 機関 |
|---|---|
| Tianli Wen | Aletheia Analyst Network Limited |
| Brian Skorney | Baird |
| Peter Lawson | Barclays |